Budesonide-Based Triple Therapy Shows Best Benefit Over Dual

triple therapy  Background: non-bismuth sequential therapy was suggested as a first-line anti-Helicobacter pylori treatment alternative to standard triple therapy Eradication rates were 80% with quadruple therapy and 55% with triple therapy Usually, the side-effects of quadruple therapy are common when

Triple therapy combining a proton pump inhibitor with two antibiotics, preferably Clarithromycin and Amoxicillin , is the first-choice treatment The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of

Clarithromycin triple◊, PPI (standard* or double therapy should be avoided ‡ Hybrid therapy has not been universally endorsed as an option for first-line Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication